Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 216

Related Citations for PubMed (Select 23851982)

1.

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.

Kiyota M, Kuroda J, Yamamoto-Sugitani M, Shimura Y, Nakayama R, Nagoshi H, Mizutani S, Chinen Y, Sasaki N, Sakamoto N, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M.

Apoptosis. 2013 Nov;18(11):1437-46. doi: 10.1007/s10495-013-0882-y.

PMID:
23851982
2.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST.

Nat Med. 2012 Mar 18;18(4):521-8. doi: 10.1038/nm.2713.

PMID:
22426421
3.

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.

Cancer Res. 2005 Oct 15;65(20):9436-44.

4.

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12. Epub 2006 Sep 22. Erratum in: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16614.

5.

The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.

Bozkurt S, Özkan T, Özmen F, Baran Y, Sunguroğlu A, Kansu E.

Hematology. 2013 Jul;18(4):217-23. doi: 10.1179/1607845412Y.0000000056. Epub 2013 Jan 25.

PMID:
23394612
6.

ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.

Exp Hematol. 2012 May;40(5):367-78.e2. doi: 10.1016/j.exphem.2012.01.004. Epub 2012 Jan 10.

PMID:
22240609
7.

The Bcl-2 homology domain 3 (BH3)-only proteins Bim and bid are functionally active and restrained by anti-apoptotic Bcl-2 family proteins in healthy liver.

Kodama T, Hikita H, Kawaguchi T, Saito Y, Tanaka S, Shigekawa M, Shimizu S, Li W, Miyagi T, Kanto T, Hiramatsu N, Tatsumi T, Takehara T.

J Biol Chem. 2013 Oct 18;288(42):30009-18. doi: 10.1074/jbc.M112.443093. Epub 2013 Aug 28.

8.

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.

Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A.

Cell Death Dis. 2013 May 16;4:e628. doi: 10.1038/cddis.2013.155.

9.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

10.

CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.

Shimada K, Tomita A, Minami Y, Abe A, Hind CK, Kiyoi H, Cragg MS, Naoe T.

Exp Hematol. 2012 Sep;40(9):724-737.e2. doi: 10.1016/j.exphem.2012.05.007. Epub 2012 May 24.

PMID:
22634393
11.

The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.

Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM.

J Biol Chem. 2011 Mar 18;286(11):9382-92. doi: 10.1074/jbc.M110.203638. Epub 2010 Dec 9.

12.

Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.

Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, Taniwaki M.

Mol Cancer Res. 2010 Jul;8(7):994-1001. doi: 10.1158/1541-7786.MCR-10-0040. Epub 2010 Jun 22.

13.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.

14.

The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.

Shen Y, Shi X, Pan J.

PLoS One. 2013 Aug 29;8(8):e73059. doi: 10.1371/journal.pone.0073059. eCollection 2013.

15.

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.

Drullion C, Trégoat C, Lagarde V, Tan S, Gioia R, Priault M, Djavaheri-Mergny M, Brisson A, Auberger P, Mahon FX, Pasquet JM.

Cell Death Dis. 2012 Aug 16;3:e373. doi: 10.1038/cddis.2012.111.

16.

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.

Cancer Res. 2013 Apr 15;73(8):2428-34. doi: 10.1158/0008-5472.CAN-12-3479. Epub 2013 Feb 4.

17.

Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.

Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A.

Cancer Res. 2007 Dec 15;67(24):11867-75.

18.

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.

Li Z, Zhou S, Zhang L, Su C, Hang J, Zhao Y, Su B, Zhou C.

Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17.

PMID:
20237869
20.

Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.

Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon FX.

Cancer Biol Ther. 2007 Jun;6(6):912-9. Epub 2007 Mar 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk